比较接受恩扎卢胺联合雄激素剥夺治疗的转移性激素敏感性前列腺癌患者中监督运动与否对体能变化影响的随机对照试验(EXTEND)
单中心随机对照试验纳入26例复发前列腺癌患者,随机分至16周监督运动组(N=13,于ADT联合恩扎卢胺开始前4周启动)或常规护理组(N=13)。常规护理组第17周绝对和相对心肺适能(CRF)较基线下降、疲劳加重、生活质量变差,运动组绝对CRF、腿部力量和功能能力改善。
要点
- 常规护理组第17周绝对CRF较基线下降0.31 L/min(10.9%),相对CRF下降3.2 mL/kg/min(8.9%)。
- 第17周运动组绝对CRF组间变化+0.20 L/min,腿部力量+48.6 kg,功能能力+21.0 m。
- 常规护理组第17周疲劳加重(p=0.01)且生活质量变差(p=0.01)。
核心结论
- 这是首个随机对照试验,显示开始ADT联合恩扎卢胺治疗的患者CRF出现有临床意义的下降。
- 短期监督运动可减轻绝对CRF下降,并改善最大腿部力量和功能能力。
研究设计与样本
- 单中心随机对照试验,纳入26例接受ADT联合恩扎卢胺治疗的复发性前列腺癌患者。
- 随机分为16周监督运动组(有氧和抗阻运动,于ADT联合恩扎卢胺开始前4周启动,N=13)或常规护理组(N=13)。
- 主要终点为峰值摄氧量(VO2peak)变化,作为心肺适能(CRF)指标;次要终点包括功能能力、最大力量、身体成分、患者报告结局、安全性和可行性。
- 采用协方差分析比较第17周组间结局,并校正基线值。
主要发现
- 常规护理组(N=13)从基线至第17周绝对CRF下降0.31 L/min(10.9%;p<0.01),相对CRF下降3.2 mL/kg/min(8.9%;p=0.04)。
- 常规护理组第17周疲劳加重(p=0.01),生活质量变差(p=0.01)。
- 第17周运动组(N=13)绝对CRF组间变化+0.20 L/min(p=0.05),腿部力量+48.6 kg(p<0.01),功能能力+21.0 m(p=0.01)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Androgen deprivation therapy (ADT) and androgen receptor signaling inhibitors (ARSI) are associated with deleterious physical effects, which exercise may mitigate; however, exercise has never been studied in patients initiating treatment with ADT and an ARSI. Our objective was to determine whether supervised exercise prior to and during initial therapy could mitigate adverse effects of ADT plus enzalutamide. METHODS: We conducted a single center trial in patients with recurrent prostate cancer treated with ADT and enzalutamide. We randomized 26 patients to 16 weeks of supervised exercise (aerobic and resistance), starting 4 weeks before initiation of ADT and enzalutamide, or usual care. The primary endpoint was change in peak oxygen uptake (VO2peak) as a measure of cardiorespiratory fitness (CRF). Secondary endpoints were functional capacity, maximal strength, body composition, patient-reported outcomes, safety, and feasibility. Analysis of covariance was used to compare outcomes for groups at Week 17 adjusted for baseline values. RESULTS: The usual care group (N = 13) showed declines from baseline to week 17 in both absolute CRF (-0.31 L/min, -10.9%; p < 0.01) and relative CRF (-3.2 mL/kg/min, -8.9%; p = 0.04); worse fatigue (p = 0.01); and worse quality of life (p = 0.01). At week 17, the exercise group (N = 13) demonstrated improved absolute CRF (between-group change +0.20 L/min, p = 0.05), leg strength (+48.6 kg, p < 0.01) and functional capacity (+21.0 m, p = 0.01) at week 17. CONCLUSIONS: This is the first randomized controlled trial demonstrating a clinically significant decline in CRF in patients initiating ADT and enzalutamide. We show the effectiveness of short-term supervised exercise to mitigate declines in absolute CRF, and improve maximal leg strength and functional capacity. GOV IDENTIFIER: NCT02256111.
引用
- Harrison MR, Davis PG, Khouri MG, et al. A randomized controlled trial comparing changes in fitness with or without supervised exercise in patients initiated on enzalutamide and androgen deprivation therapy for non-metastatic castration-sensitive prostate cancer (EXTEND). Prostate Cancer Prostatic Dis. 2022. PMID: 35273377. doi:10.1038/s41391-022-00519-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。